| 0.6196 0.019 (3.09%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.89  |
1-year : | 1.05 |
| Resists | First : | 0.76 |
Second : | 0.9 |
| Pivot price | 0.6 |
|||
| Supports | First : | 0.54 | Second : | 0.45 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.61 |
| MA(100) : | 0.74 |
MA(250) : | 0.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.4 |
D(3) : | 43 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 1.54 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LEXX ] has closed below upper band by 38.3%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.63 - 0.63 | 0.63 - 0.64 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.61 - 0.62 | 0.62 - 0.62 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Wed, 03 Jun 2026
Lexaria drug platform sees record partner interest ahead of BIO - Stock Titan
Fri, 29 May 2026
Lexaria Bioscience Corp. - Common Stock (NQ: LEXX - FinancialContent
Fri, 22 May 2026
LEXX Should I Buy - Intellectia AI
Tue, 19 May 2026
New oral GLP-1 tablets from Lexaria to face Wegovy in 5-week trial - Stock Titan
Thu, 07 May 2026
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
Tue, 21 Apr 2026
Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.344e+007 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 383 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.13e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 259.5 % |
| Return on Equity (ttm) | -76 % |
| Qtrly Rev. Growth | 368000 % |
| Gross Profit (p.s.) | -245.84 |
| Sales Per Share | -408.53 |
| EBITDA (p.s.) | 1.02222e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.85 |
| Dividend | 0 |
| Forward Dividend | 381890 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|